|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–13. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shirodkar SP and Lokeshwar VB: Potential
new urinary markers in the early detection of bladder cancer. Curr
Opin Urol. 19:488–493. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen CZ, Li L, Lodish HF and Bartel DP:
MicroRNAs modulate hematopoietic lineage differentiation. Science.
303:83–86. 2004. View Article : Google Scholar
|
|
6
|
Zhao Y, Samal E and Srivastava D: Serum
response factor regulates a muscle specific microRNA that targets
Hand2 during cardiogenesis. Nature. 436:214–220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cimmino A, Calin GA, Fabbri M, Iorio MV,
Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et
al: MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl
Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sethi S, Ali S, Philip PA and Sarkar FH:
Clinical advances in molecular biomarkers for cancer diagnosis and
therapy. Int J Mol Sci. 14:14771–14784. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ling H, Fabbri M and Calin GA: MicroRNAs
and other non-coding RNAs as targets for anticancer drug
development. Nat Rev Drug Discov. 12:847–865. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu Z, Xu T, Wang L, Wang X, Zhong S, Xu C
and Shen Z: MicroRNA-145 directly targets the insulin-like growth
factor receptor I in human bladder cancer cells. FEBS Lett.
588:3180–3185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Feng Y, Liu J, Kang Y, He Y, Liang B, Yang
P and Yu Z: MiR-19a acts as an oncogenic microRNA and is
up-regulated in bladder cancer. J Exp Clin Cancer Res. 33:672014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lei Y, Hu X, Li B, Peng M, Tong S, Zu X,
Wang Z, Qi L and Chen M: MiR-150 modulates cisplatin
chemosensitivity and invasiveness of muscle-invasive bladder cancer
cells via targeting PDCD4 in vitro. Med Sci Monit. 20:1850–1857.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Inoguchi S, Seki N, Chiyomaru T, Ishihara
T, Matsushita R, Mataki H, Itesako T, Tatarano S, Yoshino H, Goto
Y, et al: Tumour-suppressive microRNA-24–1 inhibits cancer cell
proliferation through targeting FOXM1 in bladder cancer. FEBS Lett.
588:3170–3179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang X, Wu J, Lin Y, Zhu Y, Xu X, Liang Z,
Li S, Hu Z, Zheng X and Xie L: MicroRNA-320c inhibits tumorous
behaviors of bladder cancer by targeting Cyclin-dependent kinase 6.
J Exp Clin Cancer Res. 33:692014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi L, Jiang D, Sun G, Wan Y, Zhang S,
Zeng Y, Pan T and Wang Z: miR-335 promotes cell proliferation by
directly targeting Rb1 in meningiomas. J Neurooncol. 110:155–162.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang
X, Jiang L, Sun Z, Miao Z and Xu H: MicroRNA-335 acts as a
metastasis suppressor in gastric cancer by targeting Bcl-w and
specificity protein 1. Oncogene. 31:1398–1407. 2012. View Article : Google Scholar :
|
|
17
|
Yan J, Jiang N, Huang G, Tay JL, Lin B, Bi
C, Koh GS, Li Z, Tan J, Chung TH, et al: Deregulated MIR335 that
targets MAPK1 is implicated in poor outcome of paediatric acute
lymphoblastic leukaemia. Br J Haematol. 163:93–103. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
19
|
Murali R, Chandramohan R, Möller I, Scholz
SL, Berger M, Huberman K, Viale A, Pirun M, Socci ND, Bouvier N, et
al: Targeted massively parallel sequencing of angiosarcomas reveals
frequent activation of the mitogen activated protein kinase
pathway. Oncotarget. 6:36041–36052. 2015.PubMed/NCBI
|
|
20
|
Esquela-Kerscher A and Slack FJ: Oncomirs-
microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Catto JW, Alcaraz A, Bjartell AS, De Vere
White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L,
Schlomm T and Visakorpi T: MicroRNA in prostate, bladder, and
kidney cancer: A systematic review. Eur Urol. 59:671–681. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tavazoie SF, Alarcón C, Oskarsson T, Padua
D, Wang Q, Bos PD, Gerald WL and Massagué J: Endogenous human
microRNAs that suppress breast cancer metastasis. Nature.
451:147–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fu Q, Liu X, Liu Y, Yang J, Lv G and Dong
S: MicroRNA-335 and -543 suppress bone metastasis in prostate
cancer via targeting endothelial nitric oxide synthase. Int J Mol
Med. 36:1417–1425. 2015.PubMed/NCBI
|
|
24
|
Yan Z, Xiong Y, Xu W, Gao J, Cheng Y, Wang
Z, Chen F and Zheng G: Identification of hsa-miR-335 as a
prognostic signature in gastric cancer. PLoS One. 7:e400372012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim EK and Choi EJ: Pathological roles of
MAPK signaling pathways in human diseases. Biochim Biophys Acta.
1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kamiyama M, Naguro I and Ichijo H: In vivo
gene manipulation reveals the impact of stress-responsive MAPK
pathways on tumor progression. Cancer Sci. 106:785–796. 2015.
View Article : Google Scholar : PubMed/NCBI
|
